TearSolutions
Latest round
- Series B
Last raised
- Dec 2017
Total raised
- $12M
Investors
- 7
About TearSolutions
TearSolutions, Inc. specializes in developing therapies for ocular surface diseases, notably Dry Eye Disease.131 mn. Anil Asrani serves as CEO.TearSolutions, Inc. specializes in the development of Lacripep™, a proprietary peptide therapy aimed at treating ocular surface diseases, especially Dry Eye Disease. Lacripep is derived from the Lacritin protein, functioning as a topical therapy to stabilize tear film and enhance corneal health, particularly for patients with primary Sjögren’s Syndrome.TearSolutions generates revenue through clinical trials and potential commercialization of Lacripep. Its business model involves partnerships with private and academic clinics participating in clinical trials to validate Lacripep's efficacy.In September 2024, TearSolutions, Inc. The company is focused on strengthening its product development initiatives and exploring opportunities for expansion into new markets, particularly in regions with high prevalence of ocular surface diseases.
Who invested in TearSolutions
7 investors across 2 rounds
See all investors in TearSolutions
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about TearSolutions
Who invested in TearSolutions?
TearSolutions has 7 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has TearSolutions raised?
TearSolutions has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did TearSolutions last raise money?
TearSolutions's most recent round on record is a Series B, in Dec 2017.
What does TearSolutions do?
TearSolutions is a pharmaceuticals company.
Where is TearSolutions headquartered?
TearSolutions is headquartered in Charlottesville, US.
Which VCs invest in companies like TearSolutions?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at TearSolutions's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like TearSolutions? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.